The Effect of CFTR Modulation on the Disease Progression of Cystic Fibrosis in the Era of Precision Medicine

Course Information

Therapautic Area: Pulmonolgy
Format(s): Webcast
Credit(s): N/A
Activity Dates: August 21, 2015 - August 20, 2016


This course is still available as a learning tool but has expired for CME credit.

Course Description

This educational activity is based from a live satellite symposium from the 38th European Cystic Fibrosis Conference held in Brussels, Belgium. The expert faculty for this CME activity will present a comprehensive review of the effects of CFTR modulation therapeutics on cystic fibrosis disease progression. The new era of precision medicine has arrived and many patients can now be managed on the basis of phenotypes where very good healthcare outcomes can be achieved. Cystic fibrosis patients on treatment show new progress on lung function, BMI, exercise ability, infectious complications, life expectancy, co-morbid conditions such as diabetes, liver failure, bone disease, and overall quality of life. This clinically relevant activity also includes panel discussions with case presentations to advance your skills in caring for cystic fibrosis patients.

Target Audience

Pulmonologists, pediatricians, infectious disease, and other healthcare clinicians responsible for the care of patients with cystic fibrosis.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Review the principles of precision medicine as it pertains to CFTR modulation therapeutics
  • Recognize risk factors and predictors of disease progression in the patient with cystic fibrosis
  • Evaluate the impact of CFTR modulation therapeutics on disease progression in the patient with cystic fibrosis
  • Describe current approaches to effectively manage patients on CFTR modulation therapeutics



Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME

eocme acme logo